Financial results for the second quarter and first half of 2025 for Medistim ASA

Another strong quarter for sales revenues with 16.7 % growth, ending at MNOK169.1 (MNOK 144.9). Record sales revenue for the first half year with 25.8 %growth, ending at MNOK 350.6 (MNOK 278.7).

Currency neutral sales of own products were up 18.7 % for the quarter and 25.4%for the first half.

Strong currency neutral growth for the quarter in AMERICAS and APAC, up 32.9 %and 22.9 % respectively. EMEA down 3.6 %, yet growing 8.1% in the first half.

Third-party distributor sales in Scandinavia increased 3.3 % for the quarterand21.4 % for the first half year.

Operating profit (EBIT) grew by 31.2 % for the quarter and ended at MNOK 54.1,resulting in 32.0 % EBIT margin (MNOK 41.2, 28.5 % margin). First halfoperatingprofit grew 54.5 % ending at a record MNOK 113.3, and 32.3 % EBIT margin (MNOK73.3, 26.3 % margin).

Recurring sales remained high, but strong capital sales reduce recurring salesin % to 66.8% (74.1 %) compared to the first half last year.

Medistim strengthened its commercial operation by appointing a ChiefCommercialOfficer and a new VP Sales for AMERICAS.

Solid cash position at quarter end with MNOK 96.4 after paying a dividend ofNOK6.00 per share (NOK 4.5), total MNOK 109.9 in May (MNOK 82.4). Nointerest-bearing bank loans.

https://newsweb.oslobors.no/message/653317